TOP TEN perturbations for 39824_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39824_at
Selected probe(set): 209695_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39824_at (209695_at) across 6674 perturbations tested by GENEVESTIGATOR:
precursor-B-ALL study 3 (TEL-AML1) / precursor-B-ALL study 3 (MLL-rearranged)
Relative Expression (log2-ratio):3.7984772Number of Samples:15 / 5
| Experimental | precursor-B-ALL study 3 (TEL-AML1) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
| Control | precursor-B-ALL study 3 (MLL-rearranged) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |
bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) / bone cancer study 1 (PDX; osteosarcoma, NOS; primary)
Relative Expression (log2-ratio):-3.779728Number of Samples:2 / 2
| Experimental | bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted). | |
| Control | bone cancer study 1 (PDX; osteosarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted). |
bone cancer study 1 (PDX; osteosarcoma, NOS; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Relative Expression (log2-ratio):3.7118816Number of Samples:2 / 2
| Experimental | bone cancer study 1 (PDX; osteosarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted). | |
| Control | bone cancer study 1 (PDX; myxoid chondrosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted). |
rheumatoid arthritis study 37 (mono; CD14+ CD16+) / rheumatoid arthritis study 37 (mono; CD14+ CD16-)
Relative Expression (log2-ratio):3.6576319Number of Samples:6 / 6
| Experimental | rheumatoid arthritis study 37 (mono; CD14+ CD16+) |
| Peripheral blood CD14+ CD16+ monocyte cell samples derived from patients with rheumatoid arthritis (RA). All patients were assigned to the treatment with disease-modifying antirheumatic drugs (DMARDs) i.e. tocilizumab (TCZ) and/or infliximab (IFX) and/or methotrexat (MTX). Patients characteristics: age 59.00±19.15 year; 3 males and 3 females; RF positive 4 (66.7%); ACPA positive 3 (50.0%); CRP 2.81±2.02 mg/dl; ESR 83.67±46.21 mm/hr; DAS28-CRP 5.06±1.22; DAS28-ESR 5.92±1.50; SDAI 28.76±19.03; CDAI 25.95±18.08; HAQ-DI 1.02±0.95; TJC28 8.17±6.4; SJC28 7.50±7.66; Pain, VAS 52.67±20.20; Physician GA, VAS 46.83 ±29.30 mm; Subject GA, VAS 56.00±17.61 mm | |
| Control | rheumatoid arthritis study 37 (mono; CD14+ CD16-) |
| Peripheral blood CD14+ CD16- monocyte cell samples derived from patients with rheumatoid arthritis (RA). All patients were assigned to the treatment with disease-modifying antirheumatic drugs (DMARDs) i.e. tocilizumab (TCZ) and/or infliximab (IFX) and/or methotrexat (MTX). Patients characteristics: age 59.00±19.15 year; 3 males and 3 females; RF positive 4 (66.7%); ACPA positive 3 (50.0%); CRP 2.81±2.02 mg/dl; ESR 83.67±46.21 mm/hr; DAS28-CRP 5.06±1.22; DAS28-ESR 5.92±1.50; SDAI 28.76±19.03; CDAI 25.95±18.08; HAQ-DI 1.02±0.95; TJC28 8.17±6.4; SJC28 7.50±7.66; Pain, VAS 52.67±20.20; Physician GA, VAS 46.83 ±29.30 mm; Subject GA, VAS 56.00±17.61 mm |
precursor-B-ALL study 1 (t(12;21)(p12,q22)) / normal bone marrow sample
Relative Expression (log2-ratio):3.5995588Number of Samples:58 / 74
| Experimental | precursor-B-ALL study 1 (t(12;21)(p12,q22)) |
| Bone marrow samples of patients with precursor B-ALL (t(12;21)(p12,q22)/TEL-AML1). | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |
pancreatic islet study 3 (re-differentiated; PPRF; 6d) / normal pancreatic islet sample
Relative Expression (log2-ratio):-3.396884Number of Samples:2 / 7
| Experimental | pancreatic islet study 3 (re-differentiated; PPRF; 6d) |
| Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 6 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0 ug/ml. | |
| Control | normal pancreatic islet sample |
| Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation. |
colorectal adenoma study 7 (colonic crypt) / normal colonic crypt epithelial cell sample
Relative Expression (log2-ratio):3.3930254Number of Samples:5 / 5
| Experimental | colorectal adenoma study 7 (colonic crypt) |
| Colonic crypt epithelial cell samples obtained by laser capture microdissection (LCM) from patients with colorectal adenoma. | |
| Control | normal colonic crypt epithelial cell sample |
| Histopathological normal colonic crypt epithelial cells obtained by laser capture microdissection (LCM) from the distant normal colon of patients with colorectal cancer. |
colorectal cancer study 33 (carcinoma; colonic crypt) / normal colonic crypt epithelial cell sample
Relative Expression (log2-ratio):3.293952Number of Samples:5 / 5
| Experimental | colorectal cancer study 33 (carcinoma; colonic crypt) |
| Colonic crypt epithelial cell samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma. | |
| Control | normal colonic crypt epithelial cell sample |
| Histopathological normal colonic crypt epithelial cells obtained by laser capture microdissection (LCM) from the distant normal colon of patients with colorectal cancer. |
pancreatic islet study 3 (re-differentiated; PPRF; 4d) / normal pancreatic islet sample
Relative Expression (log2-ratio):-3.2553263Number of Samples:2 / 7
| Experimental | pancreatic islet study 3 (re-differentiated; PPRF; 4d) |
| Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 4 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0ug/ml. | |
| Control | normal pancreatic islet sample |
| Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation. |
precursor-B-ALL study 3 (MLL-rearranged) / precursor-B-ALL study 3 (BCR-ABL)
Relative Expression (log2-ratio):-3.2397776Number of Samples:5 / 4
| Experimental | precursor-B-ALL study 3 (MLL-rearranged) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
| Control | precursor-B-ALL study 3 (BCR-ABL) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(9;22)(q34;q11.2)/BCR-ABL1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |